Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 11/20 | 0.66 |
| ▸ | MAPT | P10636 | 8/20 | 0.66 |
| ▸ | RECQL | P46063 | 2/20 | 0.66 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 5/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.58 |
| ▸ | HPGD | P15428 | 4/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.47 |
| ▸ | CNR2 | P34972 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14689232 | 0.91 | LMNA (0.69) | LMNAMAPTRECQLL3MBTL1MEN1 | |
| SCHEMBL14689242 | 0.90 | LMNA (0.63) | LMNAMAPTRECQLL3MBTL1MEN1 | |
| SCHEMBL14689385 | 0.88 | CNR2 (0.63) | LMNAMAPTRECQLL3MBTL1MEN1 | |
| SCHEMBL18925969 | 0.84 | MAPT (0.70) | LMNAMAPTRECQLL3MBTL1MEN1 | |
| SCHEMBL16709546 | 0.83 | LMNA (0.56) | LMNAMAPTRECQLL3MBTL1MEN1 | |
| SCHEMBL14689726 | 0.81 | LMNA (0.54) | LMNAMAPTRECQLL3MBTL1MEN1 | |
| SCHEMBL411822 | 0.81 | LMNA (1.00) | LMNAMAPTRECQLL3MBTL1MEN1 | |
| SCHEMBL14690146 | 0.81 | LMNA (0.53) | LMNAMAPTRECQLL3MBTL1MEN1 | |
| SCHEMBL14689339 | 0.79 | CNR2 (0.52) | LMNAMAPTRECQLL3MBTL1MEN1 | |
| SCHEMBL12311151 | 0.78 | CNR2 (0.56) | LMNAMAPTMEN1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9962368-B2 | Pro-neurogenic compounds | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2018-05-08 | — | — | US | disclosed |
| US-9616048-B2 | Anti-depression compounds | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2017-04-11 | — | — | US | disclosed |
| US-20160206596-A1 | Anti-depression Compounds | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2016-07-21 | — | — | US | disclosed |
| US-9162980-B2 | Anti-depression compounds | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2015-10-20 | — | — | US | disclosed |
| US-20140343018-A1 | Anti-depression Compounds | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2014-11-20 | — | — | US | disclosed |
| US-8877797-B2 | Methods for treating Parkinson's disease using pro-neurogenic compounds | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2014-11-04 | — | — | US | disclosed |
| US-8735440-B2 | Methods for treating amyotrophic lateral sclerosis using pro-neurogenic compounds | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2014-05-27 | — | — | US | disclosed |
| US-20130190273-A1 | Methods for Treating Amyotrophic Lateral Sclerosis Using Pro-Neurogenic Compounds | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2013-07-25 | — | — | US | disclosed |
| US-20130184271-A1 | Methods for Treating Parkinson's Disease Using Pro-Neurogenic Compounds | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2013-07-18 | — | — | US | disclosed |
| US-20130040977-A1 | Pro-Neurogenic Compounds | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2013-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130184271-A1 | Methods for Treating Parkinson's Disease Using Pro-Neurogenic Compounds | BDNF, GAP43, NES | LMNA 212/4885MAPT 141/4885RECQL 2782/4885 |
| US-20130190273-A1 | Methods for Treating Amyotrophic Lateral Sclerosis Using Pro-Neurogenic Compounds | BDNF, GAP43, DCX | LMNA 67/4885MAPT 122/4885RECQL 2999/4885 |
| US-20140343018-A1 | Anti-depression Compounds | BDNF, DCX, GAP43 | LMNA 523/4885MAPT 142/4885RECQL 2553/4885 |
| US-20130040977-A1 | Pro-Neurogenic Compounds | BDNF, GAP43, DCX | LMNA 174/4885MAPT 136/4885RECQL 2885/4885 |
| US-20160206596-A1 | Anti-depression Compounds | BDNF, DCX, GAP43 | LMNA 523/4885MAPT 142/4885RECQL 2553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.